Day One To Present At The 44Th Annual J.P. Morgan Healthcare Conference
A live audio webcast of the presentation will be available by visiting the News & Events section of the Company's website at . An archived replay of the webcast will be available for 30 days following the live presentation.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by“The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development and redefine what's possible for all people living with cancer-regardless of age-starting from Day One.
Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments. The Company's pipeline includes tovorafenib (OJEMDATM) and DAY301.
Day One is based in Brisbane, California. For more information, please visit or find the Company on LinkedIn or X.
Day One uses its Investor Relations website dayonebio), its X handle and LinkedIn Home Page as a means of disseminating or providing notification of, among other things, news or announcements regarding its business or financial performance, investor events, press releases, and earnings releases, and as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
DAY ONE MEDIA
...
DAY ONE INVESTORS
LifeSci Advisors, PJ Kelleher
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment